Sonawane GA, Vikas B Gawali, VV Pande* and Kardile GN

Department of Pharmacy, NN Sattha College of Pharmacy, India

*Corresponding Author: VV Pande, Department of Pharmacy, NN Sattha College of Pharmacy, India.

Received: March 14, 2022; Published: April 26, 2022

Abstract

In early January 2019, an until that time undiscovered coronavirus, nowadays recognized as the corona virus 2019, arose from Wuhan, China, and spread worldwide, causing an enormous outbreak in many Chinese cities, including Thailand, Philippines. Republic of Korea, Japan, Viet Nam, United States, and our region. The disease is formally named as Coronavirus Disease-2019. The Taiwan CDC and Ministry of Health named it Severe Pneumonia with Novel Pathogens on January 15, 2019, and it is a fifth-group notifiable contagious disease. COVID-19 is also known as a zoonotic infection with a low to reasonable mortality risk (projected at 2-5%). It travels to Person-to-person can occur by droplet or contact transmission, hitting first-line worker’s healthcare at hazard if infection controlling is laid-back or if satisfactory special shielding kit is (PPE) unavailable. There is currently no definitive cure for COVID-19, but numerous therapies are being studied. Physicians must be mindful of the mobile or touch history of patients with well-matched signs to quickly distinguish patients and escape further dissemination.

Keywords: Corona; Diagnosis; Symptoms; Treatment

References

1. Yang X., et al. “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study”. The Lancet Respiratory Medicine5 (2020): 475-481.
2. February WHOJA. “Novel Coronavirus (2019-nCoV)”. 7 (2020): 2020.
3. Organization WH. “Coronavirus disease 2019 (COVID-19): situation report” 82 (2020).
4. Fouchier RA., et al. “Koch's postulates fulfilled for SARS virus”. Nature6937 (2003): 240.
5. Perlman S. “Another decade, another coronavirus”. Massachusetts Medical Society (2020).
6. Peiris JSM., et al. “Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study”. Lancet 9371 (2003): 1767-1772.
7. Zaki AM., et al. “Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia”. The New England Journal of Medicine19 (2012): 1814-1820.
8. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet10223 (2020): 507-513.
9. Wu Z and McGoogan JMJJ. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention”. JAMA 13 (2020): 1239-1242.
10. Rate C-FJJPoM. “Characteristics of Patients Dying in Relation to COVID-19 in Italy Onder G, Rezza G, Brusaferro S”. 23 (2020).
11. Zhou F., et al. “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study”. Lancet10229 (2020): 1054-1062.
12. Du Y., et al. “Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study”. American Journal of Respiratory and Critical Care Medicine11 (2020): 1372-1379.
13. Gao Y., et al. “Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19”. Journal of Medical Virology 10 (2020).
14. Livingston E and Bucher K. “Coronavirus disease 2019 (COVID-19) in Italy”. Journal (2020).
15. Meyers C., et al. “Lowering the transmission and spread of human coronavirus”. Journal of Medical Virology 3 (2021): 1605-1612.
16. Dong Y., et al. “Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China”. American Journal of Emergency Medicine6 (2020): e20200702.
17. Channappanavar R., et al. “T cell-mediated immune response to respiratory coronaviruses”. 59.1 (2014): 118-128.
18. Rabi FA., et al. “SARS-CoV-2 and coronavirus disease 2019: what we know so far”. Pathogens 3 (2020): 231.
19. Bosch BJ., et al. “The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex”. Journal of Virology16 (2003): 8801-8811.
20. Chen Y., et al. “Structure analysis of the receptor binding of 2019-nCoV”. Biochemical and Biophysical Research Communications1 (2020): 135-140.
21. Walls AC., et al. “Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein”. Cell 2 (2020): 281-292. e6.
22. Letko M., et al. “Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses”. Nature Microbiology4 (2020): 562-569.
23. Shu Z., et al. “Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases”. Frontiers in Medicine (2020): 1-16.
24. Belouzard S., et al. “Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites”. 106.14 (2009): 5871-5876.
25. Ou X., et al. “Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV”. Nature Communications1 (2020): 1-12.
26. Belouzard S., et al. “Mechanisms of coronavirus cell entry mediated by the viral spike protein”. Viruses 6 (2012): 1011-1033.
27. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell 2 (2020): 271-280.e8.
28. Shi J., et al. “Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2”. Sciences6494 (2020): 1016-1020.
29. Hamming I., et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis”. Journal of Pathology 2 (2004): 631-637.
30. Jia HP., et al. “ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia”. Journal of Virology23 (2005): 14614-14621.
31. Yoshikawa T., et al. “Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells”. Journal of Virology7 (2009): 3039-3048.
32. Wang M., et al. “Thrombotic regulation from the endothelial cell perspectives”. Arteriosclerosis, Thrombosis, and Vascular Biology6 (2018): e90-e95.
33. Lovren F., et al. “Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis”. American Journal of Physiology-Heart and Circulatory Physiology4 (2008): H1377-H84.
34. Jung F., et al. “COVID-19 and the endothelium”. (2020): 1-5.
35. Zeng H., et al. “Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection”. Journal of Virology2 (2012): 667-678.
36. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
37. Alhazzani W., et al. “Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)”. (2020): 1-34.
38. Vaira L., et al. “Anosmia and ageusia: common findings in COVID-19 patients”. Laryngoscope (2020): 10.
39. Yan C., et al. “Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms”. International Forum of Allergy and Rhinology (2020).
40. Lechien JR., et al. “Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter. European Study”. European Archives of Oto-Rhino-Laryngology8 (2020): 2251-2261.
41. Murray CJJM. “19 Health Service Utilization Forecasting Team, Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state in the next 4 months”. (2020).
42. Wang W., et al. “Detection of SARS-CoV-2 in different types of clinical specimens”. JAMA 18 (2020): 1843-1844.
43. Mez J., et al. “Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football”. JAMA4 (2017): 360-370.
44. Namekar M., et al. “Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immunosorbent assay for diagnosis of dengue virus infection”. Journal of Clinical Microbiology9 (2013): 3102-3106.
45. Sethuraman N., et al. “Interpreting diagnostic tests for SARS-CoV-2”. JAMA22 (2020): 2249-2251.
46. Guo G., et al. “Pressure-Transient Behavior for a Horizontal Well Intersecting Multiple Random Discrete Fractures”. paper SPE.28390:25-8.
47. Bond K., et al. “Post-market validation of three serological assays for COVID-19”. Melbourne, Australia: Doherty Institute (2020).
48. Calvet G., et al. “Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study”. The Lancet Infectious Diseases6 (2016): 653-660.
49. Alhazzani W., et al. “Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)” . Intensive Care Medicine (2020): 1-34.

Citation

Citation: VV Pande., et al. “Covid-19 Overview". Acta Scientific Microbiology 5.5 (2022): 101-109.

Copyright

Copyright: © 2022 VV Pande., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.